Elite in Graft Versus Host Disease (GvHD)

Dr. Ran Reshef

Hematology | Hematology Oncology
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Elite in Graft Versus Host Disease (GvHD)
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ran Reshef is a Hematologist and a Hematologist Oncology provider in New York, New York. Dr. Reshef is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 147 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 64 articles and participated in 3 clinical trials in the study of Graft Versus Host Disease (GvHD).

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
161 Fort Washington Ave, New York, NY 10032
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Biological, Device, Drug
Study Drugs: IMA203 Product, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Biological
Study Drugs: TAK-007, Chemotherapy Agents
Study Phase: Phase 2
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Device, Drug
Study Drug: IMA202
Study Phase: Phase 1
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Diagnostic test, Biological
Study Drugs: IMA201, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Study Phase: Phase 1
Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease
Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Itacitinib, Tocilizumab
Study Phase: Phase 1
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 21, 2023
Intervention Type: Genetic, Drug
Study Drugs: Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Drug, Genetic
Study Drugs: Fludarabine, Cyclophosphamide, Anti-CD20 CAR-T Cells
Study Phase: Phase 1/Phase 2
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Drug
Study Drugs: Natalizumab, Steroids
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
View 13 Less Clinical Trials

147 Total Publications

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 16, 2025
Similar Doctors
Sergio A. Giralt
Elite in Graft Versus Host Disease (GvHD)
Dr. Sergio A. Giralt
Hematology Oncology | Hematology | Oncology
Elite in Graft Versus Host Disease (GvHD)
Dr. Sergio A. Giralt
Hematology Oncology | Hematology | Oncology

Mskcc Clinical Practice Plan

1275 York Ave, 
New York, NY 
 (5.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sergio Giralt is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Giralt is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Graft Versus Host Disease (GvHD)
Dr. Doris M. Ponce
Hematology Oncology | Hematology | Oncology
Elite in Graft Versus Host Disease (GvHD)
Dr. Doris M. Ponce
Hematology Oncology | Hematology | Oncology

Mskcc Clinical Practice Plan

1275 York Ave, 
New York, NY 
 (5.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Doris Ponce is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Ponce is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). Her top areas of expertise are Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Splenectomy.

Benedetto J. Bruno
Elite in Graft Versus Host Disease (GvHD)
Dr. Benedetto J. Bruno
Hematology
Elite in Graft Versus Host Disease (GvHD)
Dr. Benedetto J. Bruno
Hematology
240 E 38th St, 
New York, NY 
 (6.6 miles away)
646-501-4818
Languages Spoken:
English
See accepted insurances

Benedetto Bruno is a Hematologist in New York, New York. Dr. Bruno is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Leukemia, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reshef's expertise for a condition
ConditionClose
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile